HIGHLIGHTS
SUMMARY
2022, 23, 14073. https://doi.org/10.3390/ijms232214073 2 of 15 anti-CTLA-4, anti-PD-1, or anti-PD-L1 therapies facilitates T_cell activation and prevents their exhaustion, thus facilitating an immune_response against cancer. The activated DCs then migrate to the draining lymph nodes, present the cancerous antigens to T_cells, and elicit adaptive immune_responses. Indeed, TTFields concomitant with anti-PD-1 have shown efficacy in_vivo and are currently under clinical investigation for the treatment of NSCLC (LUNAR trial, NCT02973789; EF-36/KEYNOTE-B36 trial, NCT04892472). In Vivo To evaluate an immune_response in_vivo . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.